Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus CLOXACILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus CLOXACILLIN SODIUM.
BACTOCILL vs CLOXACILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Cloxacillin is a beta-lactam antibiotic that binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidases and thus preventing the cross-linking of peptidoglycan chains. This leads to cell lysis and death, primarily mediated by autolytic enzymes. It is resistant to penicillinase (beta-lactamase) produced by staphylococci.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250-500 mg orally every 6 hours on an empty stomach; 250 mg - 2 g IV/IM every 4-6 hours depending on severity; maximum 12 g/day for serious infections.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
0.5-1.1 hours in adults with normal renal function; prolonged in neonates, elderly, and renal impairment (up to 2-4 hours in anuria)
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary/fecal (small amount, <10%)
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic